Tian Zhang: CtDNA to replace radiology for disease recurrence?

Tian Zhang posted on X:

“Fiery discussion on minimal residual disease for bladder cancer — ctDNA to replace radiology for disease recurrence? Tom Powles says emphatically yes. Brian Rini says maybe complement radiology. We need to await Alliance for Clinical Trials in Oncology Modern trial from Matt Galsky and Stephanie Berg.”

Source: Tian Zhang/X

Tian Zhang is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She specializes in the diagnosis and treatment of genitourinary malignancies. She has gained an international reputation developing clinical trials in kidney, prostate, and bladder cancers. She serves as the study chair for PDIGREE, a phase III trial in metastatic renal cell carcinoma.

She serves on numerous committees, including as Co-chair of the National Cancer Institute Genitourinary (GU) Steering Committee Renal Task Force and as Chair of the Chinese American Hematologist and Oncologist Network (CAHON) Academic Committee. She is a member of several ASCO clinical management guidelines committees as well as the Alliance for Clinical Trials in Oncology, GU Oncology, and Immuno-Oncology Committees.

She has received multiple peer-reviewed grants, a Resident Research Mentoring Award from Duke, and, notably, the 2021 Cancer Prevention & Research Institute of Texas (CPRIT) Scholar Rising Stars Award.